The present disclosure relates to an isolated monoclonal antibody that specifically binds to the C1 domain of human von Willebrand factor and competes for binding to the C1 domain of human von Willebrand factor with the antibody obtainable from hybridoma deposited as CNCM-I-4483. Particularly, said embodiment is selected from the group consisting of a murine antibody, a chimeric antibody, a humanized antibody, and a human antibody. Antibodies of the present disclosure are presented to be useful in an antithrombotic treatment to prevent the formation of thrombus, which can be either a non- occlusive thrombus or an occlusive thrombus.
